A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2016
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
- Indications Ebola virus infections; Marburg virus disease
- Focus Adverse reactions
- Sponsors Crucell Holland
- 07 Dec 2016 Status changed from active, no longer recruiting to completed.
- 14 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.
- 29 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.